CN103121996B - 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 - Google Patents

用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 Download PDF

Info

Publication number
CN103121996B
CN103121996B CN201210488042.5A CN201210488042A CN103121996B CN 103121996 B CN103121996 B CN 103121996B CN 201210488042 A CN201210488042 A CN 201210488042A CN 103121996 B CN103121996 B CN 103121996B
Authority
CN
China
Prior art keywords
fluoro
alkyl
iodo
pyridin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201210488042.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103121996A (zh
Inventor
A·古托普鲁斯
B·C·小艾斯丘
X·陈
S·卡拉
H·余
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Publication of CN103121996A publication Critical patent/CN103121996A/zh
Application granted granted Critical
Publication of CN103121996B publication Critical patent/CN103121996B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201210488042.5A 2006-04-19 2007-04-18 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 Expired - Fee Related CN103121996B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79307306P 2006-04-19 2006-04-19
US60/793,073 2006-04-19
CN200780014073.4A CN101426766B (zh) 2006-04-19 2007-04-18 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200780014073.4A Division CN101426766B (zh) 2006-04-19 2007-04-18 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物

Publications (2)

Publication Number Publication Date
CN103121996A CN103121996A (zh) 2013-05-29
CN103121996B true CN103121996B (zh) 2015-10-21

Family

ID=38357968

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201210488042.5A Expired - Fee Related CN103121996B (zh) 2006-04-19 2007-04-18 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物
CN200780014073.4A Expired - Fee Related CN101426766B (zh) 2006-04-19 2007-04-18 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200780014073.4A Expired - Fee Related CN101426766B (zh) 2006-04-19 2007-04-18 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物

Country Status (14)

Country Link
US (1) US8076486B2 (enExample)
EP (1) EP2013180A1 (enExample)
JP (1) JP5525812B2 (enExample)
KR (1) KR20090005195A (enExample)
CN (2) CN103121996B (enExample)
AR (1) AR060807A1 (enExample)
AU (1) AU2007240860A1 (enExample)
BR (1) BRPI0711625A2 (enExample)
CA (1) CA2644425A1 (enExample)
EA (1) EA200802050A1 (enExample)
IL (1) IL194546A0 (enExample)
MX (1) MX2008013308A (enExample)
WO (1) WO2007123936A1 (enExample)
ZA (1) ZA200807263B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123939A2 (en) * 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
EP2231636B1 (en) * 2007-12-07 2011-09-14 Novartis AG Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
CA2789696C (en) 2010-02-25 2017-11-07 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
WO2016142894A1 (en) * 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
MA42145B1 (fr) 2015-05-20 2020-05-29 Amgen Inc Triazoles agonistes du récepteur apj
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US11186554B2 (en) 2017-05-03 2021-11-30 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
WO2019040380A1 (en) 2017-08-21 2019-02-28 Vivace Therapeutics, Inc. BENZOSULFONYL COMPOUNDS
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019113236A1 (en) 2017-12-06 2019-06-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
EP3720438B1 (en) * 2017-12-07 2023-08-30 Amplyx Pharmaceuticals, Inc. Heterocycle substituted pyridine derivative antifungal agents
CN110317190A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑-羧酸酯类衍生物在医药领域的应用
EP3788037A1 (en) 2018-05-01 2021-03-10 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CA3100503A1 (en) 2018-05-16 2019-11-21 Vivace Therapeutics, Inc. Oxadiazole compounds
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CN115279368B (zh) * 2019-11-20 2024-05-24 维瓦斯治疗公司 杂芳基化合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス， インコーポレイテッド 併用療法
CN118973580A (zh) 2022-04-08 2024-11-15 米拉蒂治疗股份有限公司 包含sos1抑制剂和mek抑制剂的组合疗法
WO2025054260A1 (en) * 2023-09-07 2025-03-13 Kinnate Biopharma Inc. Inhibitors of mek kinase
EP4788839A1 (en) 2023-10-03 2026-08-12 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056789A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Mek inhibiting oxa- and thia-diazol-2-yl phenylamine derivates
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
WO2006045514A1 (en) * 2004-10-20 2006-05-04 Applied Research Systems Ars Holding N.V. 3-arylamino pyridine derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534515A (ja) * 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー １−複素環置換されたジアリールアミン
GB2373245A (en) * 2001-03-12 2002-09-18 Bayer Ag Pyridinyl pyrazoles and their use for the treatment of COPD
BR0314195A (pt) * 2002-09-10 2005-07-26 Pharmacia Italia Spa Derivados de piridina substituìda como agentes antitumorais
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
AU2004229392A1 (en) * 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056789A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Mek inhibiting oxa- and thia-diazol-2-yl phenylamine derivates
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
WO2006045514A1 (en) * 2004-10-20 2006-05-04 Applied Research Systems Ars Holding N.V. 3-arylamino pyridine derivatives

Also Published As

Publication number Publication date
MX2008013308A (es) 2008-10-27
CN101426766B (zh) 2014-03-26
EA200802050A1 (ru) 2009-04-28
US8076486B2 (en) 2011-12-13
AR060807A1 (es) 2008-07-16
ZA200807263B (en) 2009-11-25
CN103121996A (zh) 2013-05-29
EP2013180A1 (en) 2009-01-14
AU2007240860A1 (en) 2007-11-01
US20070287737A1 (en) 2007-12-13
JP5525812B2 (ja) 2014-06-18
CN101426766A (zh) 2009-05-06
KR20090005195A (ko) 2009-01-12
WO2007123936A1 (en) 2007-11-01
BRPI0711625A2 (pt) 2011-12-06
HK1127354A1 (en) 2009-09-25
CA2644425A1 (en) 2007-11-01
IL194546A0 (en) 2009-08-03
JP2009534386A (ja) 2009-09-24

Similar Documents

Publication Publication Date Title
CN101426766A (zh) 用作mek抑制剂的新颖的杂芳基取代的芳基氨基吡啶衍生物
ES2791315T3 (es) Agonistas triazoles del receptor APJ
CN111377917B (zh) 杂环类化合物、中间体、其制备方法及应用
US10730863B2 (en) Bridged bicyclic compounds as farnesoid X receptor modulators
JP7033079B2 (ja) 芳香族スルホンアミド誘導体
CN102892759B (zh) 具有犬尿氨酸产生抑制作用的含氮杂环化合物
KR102057877B1 (ko) 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도
CN102971291B (zh) 新型酰胺衍生物及其作为药物的用途
AU2023204378A1 (en) Pyridinamine-Pyridone And Pyrimidinamine-Pyridone Compounds
AU2005335298C1 (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
WO2020103817A1 (zh) TGF-βR1抑制剂及其应用
AU2013227024A1 (en) Novel piperidine compound or salt thereof
TW201623239A (zh) 新穎２－胺基－吡啶及２－胺基－嘧啶衍生物及其醫藥用途
CN107438598A (zh) 喹唑啉和喹啉化合物及其用途
JP2007505888A (ja) オキシトシン拮抗薬としての置換トリアゾール誘導体
JP2024543207A (ja) 新規ｈｄａｃ阻害剤及びその治療的使用
TW202237143A (zh) 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物
WO2023109751A1 (zh) 嘧啶或吡啶类衍生物及其医药用途
CN105399737B (zh) 噁唑烷酮类化合物及其用途
WO2018130227A1 (zh) 一种含芳环化合物、其制备方法、药物组合物及应用
WO2022032484A1 (zh) 哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用
CN101553476A (zh) 作为有丝分裂驱动蛋白抑制剂的二唑和噻二唑衍生物及其使用方法
CN103781765A (zh) 作为hdl-胆固醇升高剂的3-吡啶甲酰肼类
HK1127354B (en) Heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors
HK40130280A (en) Azolylpyridine pyridazinone amide as sos1 inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151021

CF01 Termination of patent right due to non-payment of annual fee